SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Onco Therapies Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Onco Therapies Share Price

BSE Share Price
Not Listed

Onco Therapies Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Onco Therapies Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹162 Cr.
Book Value per Share
-
P/E Ratio
0.00
Industry PE
47
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
16.00%
Return on Capital Employed (ROCE)
9.28%
Return on Assets (ROA)
4.59%
Operating Profit Margin
25.6%
Net Profit Margin
13.57%
Gross Profit Margin
22.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
103.25%
Operating Profit Growth (1 Year)
-
503.06%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹146 Cr.
Equity
₹0 Cr.
Face Value
₹10
All Time Low / High
- / -

Onco Therapies . - (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Dec'11Dec'12TTM
ROCE % -0.3%9.3%-

Growth Parameters

Sales 79.8162162
Sales YoY Gr.-103.3%-
Adj EPS -11890
YoY Gr.-NA-
BVPS (₹) 525.8617.20
Adj Net
Profit
-2.721.40
Cash Flow from Ops. -56.7-45-
Debt/CF from Ops. -4.4-3.7-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANA103.3%
Adj EPS NANANANA
BVPSNANANA17.4%
Share Price - - - -

Key Financial Parameters

Dec'11Dec'12TTM
Return on
Equity %
-2.115.60
Op. Profit
Mgn %
8.625.6NAN
Net Profit
Mgn %
-3.313.20
Debt to
Equity
21.1-
Working Cap
Days
07740
Cash Conv.
Cycle
0-20

Profit And Loss

(All Figures are in Crores.)
PARTICULARSDec'11Dec'12
Sales79.77162.13
Operating Expenses + 72.91120.76
Manufacturing Costs8.1511.46
Material Costs30.4684.97
Employee Cost 6.118.82
Other Costs 28.1915.51
Operating Profit 6.8641.37
Operating Profit Margin (%) 8.6%25.5%
Other Income + 0.051.05
Exceptional Items 00
Interest 1.385.20
Depreciation 8.1710.52
Profit Before Tax -2.6426.70
Tax 04.70
Profit After Tax -2.6422
PAT Margin (%) -3.3%13.6%
Adjusted EPS (₹)-11.091.4
Dividend Payout Ratio (%)0%0%

Valuation of Onco Therapies - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSDec'11Dec'12

Equity and Liabilities

Shareholders Fund + 126.51148.50
Share Capital 2.412.41
Reserves 124.10146.10
Debt +164.7683.77
Long Term Debt164.7664.87
Short Term Debt018.90
Minority Interest00
Trade Payables35.1828.84
Others Liabilities 124.65245.72
Total Liabilities 451.11506.84

Fixed Assets

Net Fixed Assets +130.47123.56
Gross Block148.61152.19
Accumulated Depreciation18.1428.63
CWIP 0.764.84
Investments 00
Inventories20.7433.52
Trade Receivables13.3020.64
Cash Equivalents 1.283.13
Others Assets 284.55321.14
Total Assets 451.11506.84

Cash Flow

(All Figures are in Crores.)
PARTICULARSDec'11Dec'12
Cash Flow From Operating Activity + -56.67-44.95
PBT -2.6426.70
Adjustment 10.9810.97
Changes in Working Capital -60.45-82.7
Tax Paid -4.58-4.60
Cash Flow From Investing Activity + -12.53-6.07
Capex -12.56-6.18
Net Investments 00
Others 0.040.11
Cash Flow From Financing Activity + 29.6051.40
Net Proceeds from Shares 9.790
Net Proceeds from Borrowing 00
Interest Paid -0.02-2.29
Dividend Paid 00
Others 19.8453.68
Net Cash Flow -39.600.38

Financial Ratio

PARTICULARSDec'11Dec'12
Ratios
ROE (%)-2.0916
ROCE (%)-0.349.28
Asset Turnover Ratio0.180.34
PAT to CFO Conversion(x)N/A-2.04
Working Capital Days
Receivable Days60.3037.80
Inventory Days94.1060.50
Payable Days421.60137.50

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Onco Therapies Ltd. - (Amalgamated) FAQs

The current trading price of Onco Therapies on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Onco Therapies stood at ₹0.00 Cr

The latest P/E ratio of Onco Therapies as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Onco Therapies as of 31-Dec-1969 is 0.00.

The 52-week high of Onco Therapies is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Onco Therapies is ₹162 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Onco Therapies Ltd. - (Amalgamated)

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×